J&J has chosen a lead vaccine candidate that it began working on in January, but it likely won’t begin testing the vaccine on people until September.
After clinical trials, the first batches of a COVID-19 vaccine could be available for emergency use authorization early next year, J&J said.
The J&J effort will be funded in part by about $420 million from the Biomedical Advanced Research and Development Authority, which is part of the Office of the Assistant Secretary for Preparedness and Response at HHS.
J&J said the funding from the government will allow it to expand manufacturing capacity to make 1 billion doses of the vaccine.
Currently, there are no approved treatments or vaccines for COVID-19.
More articles on pharmacy:
Gilead asks FDA to take back orphan drug status for COVID-19 drug
Walmart nearly criminally charged over opioid prescriptions, report finds
13 drugmakers form consortium to find COVID-19 treatments
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.